Malar rash with pulmonary hypertension and chronic obstructive pulmonary disease

Robert Ffrench-O'Carroll, Bruno Biancardi, Omar Tujjar

Department of Anaesthesia and Intensive Care, Sligo University Hospital, Ireland

Correspondence to
Dr Robert Ffrench-O'Carroll,
robffrench@gmail.com

Accepted 17 June 2017

DESCRIPTION

Malar rash is a fixed erythema involving the facial cheeks and nasal bridge with sparing of the nasolabial folds. It has a classic butterfly appearance (figure 1). Its causes include local and systemic diseases, including rosacea, erysipelas and systemic lupus erythematosus (SLE).¹ Rarely it occurs due to mitral stenosis with reduced cardiac output and pulmonary hypertension.² Its association with severe pulmonary hypertension from chronic obstructive pulmonary disease (COPD) is not commonly described.

We recently admitted a 76-year-old woman to our intensive care unit with dyspnoea and cough on a background of COPD. On examination she had a malar rash (figure 1) in association with a respiratory rate of 24 breaths/min, raised jugular venous pressure, peripheral oedema and signs of peripheral venous congestion including leg ulcers and hyperpigmentation of her extremities. Admitting arterial blood gas showed pO_2 of 9 kPa on 80% oxygen, pCO_2 of 5.5 kPa, pH 7.4 and HCO_3^- of 27.2 mmol/L. N-terminal pro b-type natriuretic peptide was 18 000 pg/mL. Chest X-ray showed emphysematous lungs and CT pulmonary angiography was negative for pulmonary embolism. Autoantibody screen was negative and physical examination revealed no other features of SLE.

A transthoracic echocardiogram showed severe tricuspid regurgitation with right ventricle pressure approximately 125 mm Hg, dilated right ventricle and impaired left ventricle systolic function with ejection fraction of 35% and no evidence of mitral stenosis. She was managed successfully with a combination of oxygen, diuretics, digoxin, non-invasive ventilation and antibiotics.

Pulmonary hypertension secondary to COPD is common, associated with reduced survival and may worsen during exacerbations. Rarely severe pulmonary hypertension may occur in association with relatively preserved lung function in COPD, and other causes should be considered.³

Figure 1 Erythematosus malar rash.

Learning points

- ▶ Malar rash can be due to local and systemic disease.
- ▶ The association of a malar rash with severe pulmonary hypertension should be considered in patients with risk factors, including chronic obstructive pulmonary disease (COPD).
- ▶ Diagnosis of pulmonary hypertension in COPD has important treatment and prognostic implications.

Contributors RF-O, OT and BB drafted and wrote the manuscript.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- 1 Patel LM, Lambert PJ, Gagna CE, et al. Cutaneous signs of systemic disease. *Clin Dermatol* 2011;29:511–22.
- 2 Wood P. An appreciation of mitral Stenosis. I. clinical features. *Br Med J* 1954;1:1051–63.
- 3 Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. *Eur Respir J* 2008;32:1371–85.

CrossMark

To cite: Ffrench-O'Carroll R, Biancardi B, Tujjar O. *BMJ Case Rep* Published Online First: [please include Day Month Year]. doi:10.1136/bcr-2017-220589

Copyright 2017 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <http://group.bmj.com/group/rights-licensing/permissions>.
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow